Korean Circ J.  2017 May;47(3):377-382. 10.4070/kcj.2016.0257.

Changes in 11β-Hydroxysteroid Dehydrogenase and Glucocorticoid Receptor Expression in Kawasaki Disease

• Wang J
• Zhou N
• Wu S
• Zhang X
• Su D

• KMID: 2385392
• DOI: http://doi.org/10.4070/kcj.2016.0257

Abstract

BACKGROUND AND OBJECTIVES
This study aims to investigate the significance of changes in the expression 11β-hydroxysteroid dehydrogenase (11β-HSD) and glucocorticoid receptor (GR) for the development of Kawasaki disease (KD).
SUBJECTS AND METHODS
Real-time polymerase chain reaction was performed to determine the mRNA expression levels of GR and 11β-HSD in peripheral blood monocytes, both in the acute phase of the disease and after treatment. Western blotting was performed to determine the protein expression levels of GR and 11β-HSD.
RESULTS
The expression levels of GRβ, GRβ, and 11β-HSD1 mRNA in the acute phase were significantly higher than levels at baseline (p<0.01) and after treatment (p<0.05). The 11β-HSD2 mRNA levels were lower in the acute phase than in the normal group (p<0.01), and they were significantly higher after treatment than before (p<0.01). Western blot results were consistent with the real-time PCR results. The coronary artery lesion group exhibited significantly different 11β-HSD2 expression levels from that of the group with normal coronary arteries (p<0.01).
CONCLUSION
GR and 11β-HSD expression changes in the acute phase of KD are important factors for regulating inflammatory responses in KD.

Keyword

Kawasaki disease; 11β-hydroxysteroid dehydrogenase; Receptor, glucocorticoid

MeSH Terms

Blotting, Western
Coronary Vessels
Monocytes
Mucocutaneous Lymph Node Syndrome*
Oxidoreductases*
Real-Time Polymerase Chain Reaction
Receptors, Glucocorticoid*
RNA, Messenger
Oxidoreductases
RNA, Messenger
Receptors, Glucocorticoid

Figure

• 

  Fig. 1 RT-PCR results of GR mRNA in peripheral blood monocytes in the KD group before and after treatment and in the control group. *p<0.01, **p<0.05. GR: glucocorticoid receptor, mRNA: messenger ribonucleic acid, KD: Kawasaki disease, IVIG: intravenous immunoglobulin.

• 

  Fig. 2 Expression of 11β-HSD mRNA in peripheral blood monocytes of KD patients before and after treatment. *p<0.01, **p<0.05. 11β-HSD: 11β-hydroxysteroid dehydrogenase, mRNA: messenger ribonucleic acid, KD: Kawasaki disease, IVIG: intravenous immunoglobulin.

• 

  Fig. 3 Western blot results. *p<0.01. GR: glucocorticoid receptor, 11β-HSD: 11β-hydroxysteroid dehydrogenase, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, IVIG: intravenous immunoglobulin.

• 

  Fig. 4 Expression of 11β-HSD mRNA in monocytes of the CAL group. *p<0.01. and the CAN group. GR: glucocorticoid receptor, CAL: coronary artery lesion, 11β-HSD: 11β-hydroxysteroid dehydrogenase, CAN: coronary artery normal.

Reference

1. Weng KP, Ou SF, Lin CC, Hsieh KS. Recent advances in the treatment of Kawasaki disease. J Chin Med Assoc. 2011; 74:481–484.

2. Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008; 93:142–146.

3. Kobayashi T, Kobayashi T, Arekawa H. Prednisolone therapy for Kawasaki disease. Nihon Rinsho. 2014; 72:1623–1628.

4. Jibiki T, Kato I, Shiohama T, et al. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease. Pediatr Int. 2011; 53:729–735.

5. Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J. 2010; 29:978–979.

6. Lim YJ, Jung JW. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease. Yonsei Med J. 2014; 55:1260–1266.

7. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012; 379:1613–1620.

8. Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol. 2009; 156:689–712.

9. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011; 335:2–13.

10. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005; 47:232–234.

11. Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association. Clinical treatment recommendations of coronary artery lesions in Kawasaki disease. Chin J Pediatr. 2012; 50:746–749.

12. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007; 157:545–559.

13. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med. 2002; 165:983–991.

14. Kino T, Su YA, Chrousos GP. Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci. 2009; 66:3435–3448.

15. Garbrecht MR, Schmidt TJ, Krozowski ZS, Snyder JM. 11Beta-hydroxysteroid dehydrogenase type 2 and the regulation of surfactant protein A bydexamethasone metabolites. Am J Physiol Endocrinol Metab. 2006; 290:E653–E660.

16. Holmes MC, Sangra M, French KL, et al. 11Beta-hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoid. Neuroscience. 2006; 137:865–873.

17. Sano S, Nakagawa Y, Iwashima S, et al. Dynamics of endogenous glucocorticoid secretion and its metabolism in Kawasaki disease. Steroids. 2010; 75:848–852.

18. Ignatova ID, Kostadinova RM, Goldring CE, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells. Am J Physiol Endocrinol Metab. 2009; 296:E367–E377.

19. Sai S, Esteves CL, Kelly V, et al. Glucocorticoid regulation of the promoter of 11beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta. Mol Endocrinol. 2008; 22:2049–2060.

20. Chapman KE, Gilmour JS, Coutinho AE, Savill JS, Seckl JR. 11Beta-hydroxysteroid dehydrogenase type 1--a role in inflammation? Mol Cell Endocrinol. 2006; 248:3–8.

21. D'Attilio L, Díaz A, Santucci N, et al. Levels of inflammatory cytokines, adrenal steroids, and mRNA for GRα, GRβ and 11βHSD1 in TB pleurisy. Tuberculosis (Edinb). 2013; 93:635–641.

22. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012; 129:e17–e23.

23. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013; 99:76–82.